Does Abbott Labs Still Pass My Test After Earnings?

Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.

Jim Cramer: Here's How We're Going to Beat Covid-19

Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.

MultiPlan Can Plod Along With Slow, but Consistent Growth

The decline of the healthcare firm's stock offers the opportunity to sell out-of-the-money puts for an attractive premium.

Walgreens Does Not Show a Bullish Pattern Ahead of Earnings

The company is set to report earnings on Thursday.

How to Play Social Capital III's Purchase of Clover Health

It's not the merits of the deal from a long-term perspective I want to trade. It's the beat down of the stock from above $13 to under $11.

Exact Sciences Stock Could Sprint Higher in the Weeks Ahead

EXAS is likely to consolidate its recent gains.

Opko Health Successfully Tests a Bottom and Is Ready to Rise

A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.

GoodRx Hasn't Been Public Long But Here's What We Know

GDRX will not stay in a tight range for long.

Jim Cramer: The President's Behavior Towards Covid-19

I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?